[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-cancer-stage-iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-cancer-stage-iv":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":38,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":5},"100610263","a-study-of-meaning-centered-therapy-for-mexican-adults-with-advanced-cancer-100610263",false,"NCT07225309","A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer","Trial of Meaning Centered Psychotherapy for Mexican Patients With Advanced Cancer","Patient Eligibility Criteria:\n\nA patient cannot be considered eligible for this study unless ALL of the following conditions are met. Participant eligibility will be determined by an initial EMR review followed by a self-report screener and suicide risk assessment.\n\nInclusion Criteria:\n\nEMR Criteria\n\n\\- Documentation of Disease\n\n* Pathologically confirmed breast, prostate, colorectal, thyroid, cervix, uteri, or lung - solid tumor cancer (either most recent or new diagnosis)\n\n  * Definition of Disease \\[or Measurable Disease\\]\n* Diagnosed with stages III or IV\n\n  * Prior Treatment\n* Receiving ambulatory care at INCan\n\nSelf-Report Criteria\n\n* Age ≥ 18 years\n* Able to read and communicate in Spanish determined by the question: \"Can you read and communicate in Spanish? Yes\u002FNo\"\n* Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention\n* Providing care (or services) to Mexican cancer patients at INCan\n* Has access to internet and an electronic device\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nEMR Criteria\n\n* Prior Treatment\n\n  * Received psychological or psychiatric care at INCan in the last 3 months\n  * In the judgment of the treating physician, protocol investigators, and\u002For study staff, presence of cognitive impairment (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For study participation\n  * Diagnosed with a serious psychiatric condition\n\nSelf-Report Criteria\n\n* Received psychological or psychiatric care outside of INCan in the last 3 months\n* Presence of suicide risk determined by the Columbia-Suicide Severity Rating Scale\n* Too ill to participate determined by the question: \"Do you feel too ill to participate because of communication problems, uncontrollable pain, or other symptoms that prevent you from participating?\"\n\nProvider Eligibility Criteria:\n\nInclusion Criteria Self-Report Criteria\n\n* Age ≥ 18 years\n* Able to read and communicate in Spanish determined by the question: \"Can you read and communicate in Spanish? Yes\u002FNo\"\n* Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention\n* Providing care (or services) to Mexican cancer patients at INCan\n* Has access to internet and an electronic device\n* Agrees to be audio-recorded","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, including how the therapy is designed, outside factors, available resources, and how the people involved affect how well MCP-L works.",[26,27,28,29,30,31,32,33,34,35,36,37],"Breast Cancer","Prostate Cancer","Colorectal Cancer","Thyroid Cancer","Breast Cancer Stage III","Breast Cancer Stage IV","Prostate Cancer Stage III","Prostate Cancer Stage IV","Colorectal Cancer Stage III","Colorectal Cancer Stage IV","Thyroid Cancer Stage III","Thyroid Cancer Stage IV",[39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Breast cancer","Breast cancer Stage III","Breast cancer Stage IV","Prostate cancer","Prostate cancer Stage III","Prostate cancer Stage IV","Colorectal cancer","Colorectal cancer Stage III","Colorectal cancer Stage IV","Thyroid cancer","Thyroid cancer Stage III","Thyroid cancer Stage IV","25-240","Memorial Sloan Kettering Cancer Center","RECRUITING","2026-06-18",{"date":56,"type":57},"2026-06-22","ACTUAL",{"date":59,"type":57},"2026-05-01",{"date":61,"type":20},"2029-04-13",{"name":52,"class":63},"OTHER",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100630276","phase-1-drug-repurposing-in-thyroid-carcinoma-a-feasibility-trial-100630276","NCT07485569","Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","Network Pharmacology-based Personalized Drug Repurposing in Thyroid Carcinoma: a Pilot Feasibility Trial","REPOTHYROID-II","Inclusion Criteria:\n\n* Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available.\n* Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).\n* Measurable disease per RECIST 1.1\n* ECOG performance status ≤ 2\n* Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception.\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inability to obtain a (new) biopsy for molecular profiling\n* Pregnancy or breastfeeding.\n* Other active malignancies requiring therapy.\n* Neutropenia (ANC \\\u003C 1.5 × 10⁹\u002FL).\n* Severe uncontrolled medical conditions (renal, cardiac, liver, respiratory).",{"count":73,"type":20},10,[75],"PHASE1","This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.",[37,78,79,80],"Anaplastic Thyroid Cancer","Differentiated Thyroid Cancer","Poorly Differentiated Thyroid Carcinoma",[82,48,83,84],"Drug repurposing","Network pharmacology","Personalized therapy","NOT_YET_RECRUITING","2026-06-17",{"date":56,"type":57},{"date":89,"type":20},"2026-06-01",{"date":91,"type":20},"2027-09-01",{"name":93,"class":63},"Radboud University Medical Center"]